ライフサイエンスコーパス: SCFA

1 SCFA also suppressed effector T cell induction in the CL

2 SCFA amounts differed in BAD, controls and IBS-D, with s

3 SCFA are protective in various animal models of inflamma

4 SCFA supplementation enhances IL-22 production, which pr

5 SCFA supplementation in the drinking water of male mice

6 SCFA-treated diabetic mice were protected from nephropat

7 SCFAs generate IL-10(+) regulatory T cells, which may pr

8 SCFAs have been shown to have anti-inflammatory properti

9 SCFAs inhibited IFN-gamma and IL-17A production in perip

10 SCFAs maintained intestinal barrier function and reduced

11 SCFAs metabolically regulate T cells and change the phen

12 SCFAs producing bacteria (Lachnospiraceae and Ruminococc

13 SCFAs promote human CD4(+) T cell IL-22 production.

14 SCFAs upregulate IL-22 production by promoting aryl hydr

15 and related bacterial strains, we selected 4 SCFA-producers (Bifidobacterium longum, Clostridium symb

16 that pentanoate, a physiologically abundant SCFA, is a potent regulator of immunometabolism.

17 Upon treatment with acetate SCFA or FFAR2- and FFAR3-specific synthetic agonists, hu

18 s, in particular the short-chain fatty acid (SCFA) acetate, are believed to be involved in these proc

19 pionic acid (PPA), a short-chain fatty acid (SCFA) and a product of dys-biotic ASD gut, on human neur

20 Faecal short chain fatty acid (SCFA) and urinary volatile organic compounds (VOCs) were

21 iota composition and short-chain fatty acid (SCFA) concentrations in parallel with host immunometabol

22 c sequence and fecal short-chain fatty acid (SCFA) levels were available(2), then combined this infor

23 um butyrate (NaB), a short chain fatty acid (SCFA) normally produced in the intestine by gut microbio

24 ency (P = 0.02), and short-chain fatty acid (SCFA) producer Lachnospira [false-discovery rate (FDR)-c

25 f gut microbiota and short-chain fatty acid (SCFA) profiles across different stages of gestation, lac

26 The short-chain fatty acid (SCFA) receptor FFAR3 was found to be highly expressed in

27 licate the mammalian short-chain fatty acid (SCFA) receptors, FFAR2 and FFAR3- in colitis, arthritis

28 microRNA (miRNA) and short chain fatty acid (SCFA) signatures to correlate their association with the

29 Short-chain fatty acid (SCFA) species altered after antibiotic treatment were id

30 te (NaBu), a form of short-chain fatty acid (SCFA), acts classically as a potent anti-angiogenic agen

31 colon and triggering short chain fatty acid (SCFA)-mediated intracellular acidification.

32 on of anaerobes, and short-chain fatty acid (SCFA)-producing bacteria, and an expansion of potential

33 Short chain fatty acids (SCFA) are metabolites of intestinal bacteria resulting f

34 roperties of faecal short-chain fatty acids (SCFA) as diagnostic biomarkers for IBS.

35 Short-chain fatty acids (SCFA) were measured by HPLC.

36 emistry, intestinal short chain fatty acids (SCFA), and liver glycogen of triplicate groups of 20 red

37 Short-chain fatty acids (SCFA), formed by microbial fermentation, are believed to

38 carbohydrates into short-chain fatty acids (SCFA).

39 vels of circulating short-chain fatty acids (SCFA).

40 a relative loss of short chain fatty acids (SCFA).

41 microbiota-derived short-chain fatty acids (SCFAs) after allogeneic bone marrow transplant (allo-BMT

42 rated fiber-derived short-chain fatty acids (SCFAs) and free fatty acid receptors including GPR43 are

43 es, gut microbiota, short-chain fatty acids (SCFAs) and metabolites.

44 ne bioconversion to short-chain fatty acids (SCFAs) and the associated microbiological features.

45 KEY POINTS: The short-chain fatty acids (SCFAs) are bacterial metabolites produced during the col

46 The short-chain fatty acids (SCFAs) are bacterial metabolites produced during the col

47 Short-chain fatty acids (SCFAs) are fermented dietary components that regulate im

48 Short-chain fatty acids (SCFAs) are major products of gut microbial fermentation

49 Short-chain fatty acids (SCFAs) are metabolites present in certain foods and are

50 Short-chain fatty acids (SCFAs) are produced from dietary fiber by gut bacteria a

51 Short chain fatty acids (SCFAs) are produced in the gut by bacterial fermentation

52 Short-chain fatty acids (SCFAs) are small molecules ubiquitous in nature.

53 Short-chain fatty acids (SCFAs) butyrate and propionate are metabolites from diet

54 lprotectin, and the short-chain fatty acids (SCFAs) butyrate and propionate were determined in childr

55 tory cells, and the short chain fatty acids (SCFAs) butyrate, propionate and acetate also induce simi

56 increased levels of short-chain fatty acids (SCFAs) by enhancing abundance of SCFA-producing bacteria

57 d faecal and plasma short-chain fatty acids (SCFAs) determination.

58 Short-chain fatty acids (SCFAs) have immunomodulatory effects, but the underlying

59 Short-chain fatty acids (SCFAs) have protective effects on experimental autoimmun

60 e in IgA levels and short chain fatty acids (SCFAs) in both trachea and lungs.

61 gut microbiota and short chain fatty acids (SCFAs) in nephrolithiasis.

62 f microbial-derived short-chain fatty acids (SCFAs) including acetate, butyrate, and propionate on gr

63 t dietary fiber and short chain fatty acids (SCFAs) induced the expression of the vitamin A-convertin

64 Luminal short-chain fatty acids (SCFAs) influence gut physiological function via SCFA rec

65 dietary fiber into short chain fatty acids (SCFAs) known to be important for human health.

66 logical conditions, short-chain fatty acids (SCFAs) production, and a detailed study of the microstru

67 microbiota-derived short-chain fatty acids (SCFAs) promote IL-22 production by CD4(+) T cells and IL

68 the microbe-derived short-chain fatty acids (SCFAs) propionate and butyrate in day 100 plasma samples

69 situ production of short-chain fatty acids (SCFAs) such as propionic and butyric acids.

70 cteria that produce short-chain fatty acids (SCFAs) through gut fermentation of fiber, in CKD and dia

71 bacteria producing short-chain fatty acids (SCFAs) was tested as a more targeted and refined microbi

72 etermined by ELISA; short-chain fatty acids (SCFAs) were measured in stool samples by using gas chrom

73 Fecal short chain fatty acids (SCFAs) were measured using a liquid chromatography-mass

74 icrobiota producing short-chain fatty acids (SCFAs) with the ability to prevent inflammation.

75 ABSTRACT: The short-chain fatty acids (SCFAs), acetate, propionate and butyrate, are bacterial

76 The short-chain fatty acids (SCFAs), acetate, propionate and butyrate, are bacterial

77 file, production of short-chain fatty acids (SCFAs), and gut microbiota community structure of green

78 butyrate and other short-chain fatty acids (SCFAs), induce regulatory T cells (Tregs).

79 littermates, mainly short-chain fatty acids (SCFAs), ketones, and alcohols, and longitudinal differen

80 the hypothesis that short-chain fatty acids (SCFAs), key bioactive microbial metabolites, are the mis

81 Short-chain fatty acids (SCFAs), metabolites produced through the microbial ferme

82 We report that short-chain fatty acids (SCFAs), produced by gut microbiota as fermentation produ

83 c-treated mice with short-chain fatty acids (SCFAs), products of microbial metabolism, restores IGF-1

84 Short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate, are p

85 Short-chain fatty acids (SCFAs), such as butyrate, produced through anaerobic mic

86 n species producing short-chain fatty acids (SCFAs), such as butyrate.

87 tential mechanisms, short chain fatty acids (SCFAs), the byproducts of microbial fermentation of diet

88 Recently, short-chain fatty acids (SCFAs), which are generated by fermentation of complex c

89 he colon to produce short-chain fatty acids (SCFAs), which are proposed to have systemic anti-inflamm

90 ndgut production of short-chain fatty acids (SCFAs).

91 icrobially-produced short-chain fatty acids (SCFAs).

92 al concentration of short-chain fatty acids (SCFAs).

93 dy aimed to deliver short-chain fatty acids (SCFAs, including propionic and butyric acids) using Pick

94 Short chain fatty acids (SCFAs; e.g., acetate, propionate, and butyrate) are prod

95 metabolites called short-chain fatty acids ([SCFA)] produced during fermentation of prebiotic fiber i

96 ntified the fraction of colonic administered SCFAs that could be recovered in the systemic circulatio

97 Orally administered SCFAs induced effector (Th1 and Th17) and regulatory T c

98 The contribution of an SCFA receptor, free fatty acid receptor (FFA)3, to the e

99 We analyzed SCFA levels by high-performance liquid chromatography (H

100 cal damage, disease activity index (DAI) and SCFA concentration in stools.

101 obiota with the host metabolic functions and SCFA levels.

102 composition of SCFA-producing microbiota and SCFA production in the small intestines.

103 Microbial, miRNA and SCFA profiles were assessed using datasets from 16S rRNA

104 t between gut dysbiosis, miRNA profiling and SCFA level in response to intestinal inflammation.

105 These results shed new light on bacteria and SCFAs, which may promote the development of treatment st

106 tions in the proportion of myeloid cells and SCFAs, more specifically acetate, butyrate, and propiona

107 eased inflammation and mortality in CKD, and SCFAs have been proposed to mediate this effect.

108 esulted in different phenolic metabolite and SCFAs profiles in each colonic segment, with important h

109 icrobial profiling, shotgun metagenomics and SCFAs in 153 fecal samples from non-kidney stone (NS) co

110 pha binds directly to the Il22 promoter, and SCFAs increase HIF1alpha binding to the Il22 promoter th

111 s in the production or absorption of another SCFA, propionate, were causally related to an increased

112 lifestyle modifications leading to augmented SCFA production could be a beneficial nonpharmacological

113 obstruction, which was, in turn, induced by SCFA-induced inflammation in the ureteropelvic junction

114 erts anti-inflammatory activity, mediated by SCFAs production from its dietary fiber, by reducing the

115 elivery capsules and plasma levels of (13) C-SCFAs (13) C-glucose, (13) C-cholesterol and (13) C-fatt

116 In B cells, SCFAs increase acetyl-CoA and regulate metabolic sensors

117 ion associated with reduction of circulating SCFA may contribute to metabolic disorders promoting the

118 macronutrient composition affect circulating SCFAs.

119 tion of high-fiber diets affects circulating SCFAs, which are associated with measures of appetite an

120 , protein, or unsaturated fat on circulating SCFAs.

121 ffect of SCFAs were mediated via the cognate SCFA receptors GPR43/GPR109A, and modulated L-3,4-dihydr

122 may underlie hypertension, through deficient SCFA production and GPR43/109A signaling.

123 These results demonstrate SCFA-AhR ligand interactions in YAMC and Caco-2 cells wh

124 Animal research suggests that colon-derived SCFAs modulate feeding behavior via central mechanisms.

125 Levels of microbe-derived SCFAs are closely relevant to human health status and in

126 f systemic concentrations of microbe-derived SCFAs.

127 findings identified that microbiota-derived SCFAs modulate poststroke recovery via effects on system

128 Gut microbiota-derived SCFAs play an important role in maintaining host immune

129 on, transplantation of monocytes, or dietary SCFA or Lactobacillus probiotic supplementation was cond

130 on, transplantation of monocytes, or dietary SCFA supplementation.

131 vestigated, in depth, the impact of elevated SCFA levels on T cells and tissue inflammation in mice.

132 pathological effects of chronically elevated SCFAs.

133 The study indicated that faecal SCFA could be a non-invasive, valid and reliable biomark

134 phy-mass spectrometry revealed higher faecal SCFAs, including butyrate, propionate, valerate, isovale

135 ystolic and diastolic blood pressure, faecal SCFAs, Bacteroides plebeius and Bacteroides coprocola in

136 g of RS is effective in modulating body fat, SCFAs, early-phase insulin and GLP-1 secretion and the g

137 cal microbiota composition, plasma and fecal SCFA, energy expenditure and substrate oxidation, body c

138 ota composition and inferred function, fecal SCFA concentration, gastrointestinal (GI) symptoms, diet

139 Fecal SCFAs were affected by time but not treatment.

140 and a similar decrease was observed in fecal SCFAs among alcoholic hepatitis patients.

141 ncreatic fat, intramyocellular lipids, fecal SCFAs, blood pressure, or 24-h heart rate variability.

142 al inflammation, low concentrations of fecal SCFAs, and high systemic inflammation are significantly

143 mented with targeted quantification of fecal SCFAs, bile acids, and functional microbial genes.

144 , and fermentability by the human gut flora, SCFAs production, nitric oxide and cytokine expression o

145 Stool samples were analysed for SCFA (acetic acid, propionic acid, butyric acid, isobuty

146 In mammalian guts, SCFAs are mostly produced by anaerobic intestinal microb

147 Pre-treatment with beta-HB, SCFA receptor inhibitor, hindered neurosphere expansion

148 Maintaining a healthy, SCFA-producing microbiota is important for cardiovascula

149 oung fecal transplants contained much higher SCFA levels and related bacterial strains, we selected 4

150 However, SCFA or dietary fiber intake restores this immune defici

151 However, SCFA receptor (GPR41 or GPR43) deficiency did not affect

152 However, SCFAs can also induce Th1 and Th17 cells upon immunologi

153 Based on these findings, we examined if SCFAs promote epithelial barrier through IL-10RA-depende

154 e in the antioxidant values and an important SCFAs production were obtained, revealing the enhanced a

155 Importantly, SCFAs can induce CD4(+) effector T cells, which are high

156 producers and a concomitant augmentation in SCFA production in both breeds.

157 Significant differences in SCFA levels between different groups of biological pract

158 lactation was associated with an increase in SCFA producers and a concomitant augmentation in SCFA pr

159 mechanism involving significant increases in SCFA production and increased IgA levels.

160 etween diets; and associations of changes in SCFAs with cardiometabolic parameters.

161 lasma) was available, and the differences in SCFAs observed in the plasma samples were not recapitula

162 results suggest that strategies to increase SCFA levels could be a new dietary preventive option for

163 Milk mineral-enrichment also increased SCFA concentrations, although less pronounced.

164 nt of SCFA-producing bacteria, and increased SCFA production.

165 significantly impaired by either inhibiting SCFA production or genetic ablation of GPR43.

166 In the PG treatments, intestinal SCFA significantly decreased while plasma glucose, chole

167 uman colon by measurement of (13) C-labelled SCFA concentrations in blood.

168 whereas diarrhea, high calprotectin, and low SCFA production related to death indirectly via their mo

169 Mice with low SCFA production due to reduced dietary fiber consumption

170 Although luminal SCFAs evoke electrogenic anion secretion and smooth musc

171 we hypothesized that serum acetate, the main SCFA in circulation, increases on all high-fiber diets,

172 Oral administration of all major SCFAs, such as acetate, propionate, and butyrate, induce

173 all protective effect, blood levels of major SCFAs, such as acetate, propionate and butyrate, are sig

174 s modest positive effects on gut microbiota, SCFAs, effector memory T cells, and the acute innate imm

175 atty acids (SCFAs) by enhancing abundance of SCFA-producing bacteria.

176 f dietary fiber can alter the composition of SCFA-producing microbiota and SCFA production in the sma

177 Some derivatives of SCFA were only detected using methanol as solvent.

178 ulation of the gut microbiota, enrichment of SCFA-producing bacteria, and increased SCFA production.

179 d improved dysbiosis, promoting expansion of SCFA-producing bacteria of the genera Prevotella and Bif

180 ics and consequently decreased the extent of SCFA release, latter was 40-45% in the gastric-bypassed

181 Colonic infusions of SCFA mixtures, in concentrations and ratios reached afte

182 populations and shifts in the production of SCFA.

183 llow future evaluation and quantification of SCFA production from (13) C-labelled fibres in the human

184 However, the quantification of SCFA using conventional chromatographic approaches is of

185 fects were independent of the stimulation of SCFA receptors GPR41, GPR43, or PPAR, but instead were a

186 A detailed understanding of SCFA metabolism by the gut microbiota is necessary to un

187 findings support exogenous administration of SCFAs as a potential treatment strategy for uveitis thro

188 Administration of SCFAs reduced renal crystals.

189 Oral administration of SCFAs to mice significantly reduced the severity of alle

190 e is a burgeoning demand for the analysis of SCFAs due to an increasing academic interest of gut micr

191 present study, the systemic availability of SCFAs and their incorporation into biologically relevant

192 otective effects, and shifted the balance of SCFAs toward propionate.

193 Known health benefits of SCFAs in allergic disease can, at least in part, be expl

194 Further, using in vivo concentration of SCFAs, we demonstrated that SCFAs inhibit the growth, ge

195 etabolites, the intestinal concentrations of SCFAs and biogenic amines decreased with the dietary pro

196 tridium, and had increased concentrations of SCFAs and methyamines.

197 High concentrations of SCFAs and the acidic environment counter the competitive

198 emulsions for the colon-targeted delivery of SCFAs.

199 CFAs by coupling amidation derivatization of SCFAs with paper-loaded direct analysis in real time mas

200 To investigate the effect of SCFAs on hypertensive cardiac damage and atherosclerosis

201 o mice, suggesting that the direct effect of SCFAs on T cells can even be pro-inflammatory in the CNS

202 The cardioprotective effect of SCFAs were mediated via the cognate SCFA receptors GPR43

203 ontrast to the moderate protective effect of SCFAs, mice deficient in GPR41 or GPR43 are more resista

204 This review examines the effect of SCFAs, prebiotics, and pre- and probiotic combinations (

205 However, the effects of SCFAs on human mast cell function, including the underly

206 This Review will focus on the effects of SCFAs on the musculoskeletal system and discuss the mech

207 red eligible if they examined the effects of SCFAs, prebiotics, or synbiotics; were delivered orally,

208 This B cell-helping function of SCFAs is detected from the intestines to systemic tissue

209 , despite the overall protective function of SCFAs, SCFAs and their receptors have the potential to r

210 r analyses confirmed a substantial impact of SCFAs on microglial activation, which depended on the re

211 in vivo findings highlight the importance of SCFAs, especially butyrate as a promising therapeutic ag

212 gnificant associations between the levels of SCFAs and the infant's diet were identified.

213 ection had significantly decreased levels of SCFAs in the cecal contents that correlate with a higher

214 ntibiotic-induced decreases in the levels of SCFAs in the cecum enhances the growth and GI colonizati

215 h seem to be associated with lower levels of SCFAs in the feces from infected rats.

216 tal tract digestibilities, and production of SCFAs (P < 0.05), but its effect was in general cowpea s

217 Production of SCFAs was higher after fermentation of green coffee brew

218 ly impacts in vitro fermentation profiles of SCFAs from fibers with different chemical structures.

219 producing different amounts and profiles of SCFAs from the same carbohydrate substrates.

220 High proportion of SCFAs remaining after the intestinal digestion (~65%) sh

221 Us leading to different levels and ratios of SCFAs.

222 Reintroduction of SCFAs to fiber-depleted mice had protective effects on t

223 data emphasize an immune-modulatory role of SCFAs and their importance for cardiovascular health.

224 ive was to investigate the potential role of SCFAs in the prevention of allergy and asthma.

225 The role of SCFAs was investigated in human eosinophil function and

226 is (EAE) responses but the detailed roles of SCFAs and their receptors in regulating autoimmune CNS i

227 These findings establish the roles of SCFAs in inducing IL-22 production in CD4(+) T cells and

228 milk mineral showed no cumulative effect on SCFA formation and seemed to oppose the milk mineral-ind

229 Alterations in the amount of only one SCFA, butyrate, were observed only in the intestinal tis

230 to underpin effective strategies to optimize SCFA supply to the host.

231 -fiber, normal chow, or zero-fiber diets, or SCFAs in drinking water.

232 Oral SCFA administration attenuated uveitis severity in a mou

233 to the onset of uveitis were blunted by oral SCFA administration.

234 Butyrate, but not other SCFAs, induced SYNPO in epithelial cell lines and murine

235 Because of the seemingly paradoxical SCFA activities in regulating T cells, we investigated,

236 In parallel, SCFAs control gene expression to express molecules neces

237 ammation, and elevated gut, brain and plasma SCFA concentrations in aged stroke mice.

238 e any differences in fecal or fasting plasma SCFA concentrations or in systemic concentrations of gut

239 UCG-010, Christensenellaceae R-7 and plasma SCFAs in NT.

240 rt that one of the main bacterially produced SCFAs, propionate, activates ileal mucosal free fatty ac

241 eestablishment of a microbiota that produces SCFAs enhances clearance of Klebsiella pneumoniae, Esche

242 Pulmonary SCFAs correlated with increased oral anaerobes, such as

243 We used LC-MS to quantify SCFA concentrations in fasting serum, collected at basel

244 n, we established a novel method to quantify SCFAs by coupling amidation derivatization of SCFAs with

245 This platform was applied to quantify SCFAs in various biological samples, including feces fro

246 c administration of physiologically relevant SCFA mixtures on human substrate and energy metabolism.

247 Remarkably, SCFAs of a biological sample were quantitatively determi

248 te the overall protective function of SCFAs, SCFAs and their receptors have the potential to regulate

249 Increase in serum SCFAs was associated with increased TB susceptibility.

250 Several SCFAs-producing gut bacteria, as well as metabolic pathw

251 Of six SCFAs, the levels of two differed significantly (p-value

252 acterium, which increased fecal and systemic SCFA concentrations.

253 concentration of SCFAs, we demonstrated that SCFAs inhibit the growth, germ tube, hyphae and biofilm

254 epithelial cells (IECs), we discovered that SCFAs, particularly butyrate, enhanced IEC barrier forma

255 Although there is recent evidence that SCFAs are beneficial in allergic asthma models, the effe

256 riments presented here provide evidence that SCFAs may promote type 2 inflammation in allergic diseas

257 wide-field calcium imaging, we observed that SCFAs induced altered contralesional cortex connectivity

258 For the first time, we observed that SCFAs were able to attenuate human eosinophils at severa

259 Collectively, we show that SCFAs act via FFAR2/3 to modulate human monocyte inflamm

260 the proportions and differences between the SCFA were calculated.

261 0 production and suppressing Th17 cells, the SCFA pentanoate might be of therapeutic relevance for in

262 tic-driven increase in gut production of the SCFA butyrate was associated with improved insulin respo

263 humans, increased colonic production of the SCFA propionate acutely reduces energy intake.

264 Here, we investigated effects of the SCFA propionate in 2 different mouse models of hypertens

265 athways in the colon, the involvement of the SCFA receptor free fatty acid receptor (FFA)3, one of th

266 e total amount and the amount of each of the SCFA were measured, and the proportions and differences

267 These results suggest that the SCFA-FFA3 pathway has a novel anti-secretory function in

268 The SCFAs were mainly excreted via the lungs after oxidation

269 Here, we investigated the effects of the SCFAs (acetate, propionate, and butyrate) on mast cell-m

270 to (13) CO2 , whereas less than 0.05% of the SCFAs were excreted into urine.

271 lectron conditions provided according to the SCFAs production rate and also the carbon utilization ef

272 These SCFA-producers alleviated poststroke neurological defici

273 These SCFAs are potent preventive agents against colorectal ca

274 We show here that at low doses these SCFAs directly impact B cell intrinsic functions to mode

275 g in these B cell-intrinsic processes, these SCFAs impair intestinal and systemic T-dependent and T-i

276 In addition, all three SCFA mixtures increased fasting and postprandial plasma

277 All three SCFA mixtures increased fasting fat oxidation (P < 0.01)

278 Thus, SCFA production may be one mechanism by which microbiota

279 Thus, SCFAs, when systemically administered at levels higher t

280 GPR43 and GPR109A are critical to SCFA-mediated protection against this condition.

281 ceptors facilitated methane bioconversion to SCFAs (ranging from 1.1 to 36.7 mg acetate L(-1) d(-1),

282 03) and exhibited a trend for elevated total SCFA content (P < 0.06).

283 Total SCFAs increased in all colonic vessels with a rise in th

284 hanges in stool acetate (P = 0.02) and total SCFAs (P = 0.05) were higher in the WG group than in the

285 la OTU with equally high production of total SCFAs with propionate as the major product.

286 quations to examine change in ln-transformed SCFAs from baseline to the end of each diet; differences

287 tilized by gut microbes to produce these two SCFA from dietary carbohydrates and from amino acids res

288 As) influence gut physiological function via SCFA receptors and transporters.

289 In vitro, SCFAs modulated inflammation in renal tubular cells and

290 with metabolite differences, including VOC, SCFA and primary BAs when compared to IBS-D.

291 interactions in YAMC and Caco-2 cells where SCFAs synergistically enhance basal and ligand-induced e

292 al system and discuss the mechanisms whereby SCFAs regulate bone cells.

293 We tested whether SCFAs contribute to poor TB control in a longitudinal co

294 went four investigational days, during which SCFA mixtures (200 mmol/L) high in either acetate (HA),

295 erstanding the molecular mechanisms by which SCFAs beneficially affect physiological functions such a

296 This was associated with SCFA-dependent changes in spine and synapse densities.

297 nd women (>=30 y old); 163 participants with SCFA data were included in this analysis.

298 s well as metabolic pathways associated with SCFAs production, were considerably lower in the gut mic

299 n and mouse mast cells were co-cultured with SCFAs and assessed for degranulation after IgE- or non-I

300 In addition, we treated mice with SCFAs to examine their effect on allergic airway inflamm